Laguna Blends
1912 Enterprise Way, Suite #302 V1Y 9S9 Kelowna, BC, Canada

We have changed our Page Name to Isodiol International Inc Follow us here Isodiol International Inc

Isodiol International Inc. signs definitive licensing agreement with Canopy Growth Corporation for Canadian and international distribution News Release: https://isodiol.com/isodiol-international-inc-signs-defini/ #CanopyGrowthCorporation #TSX $WEED #CSE $ISOL #LicensingAgreement #Pot-O-Coffee #K-Cup #MarijuanaInfused #CannabisCompany... Isodiol is pleased to announce it has signed a licensing agreement with Canopy Growth Corporation (Canopy) (TSX:WEED) (https://www.canopygrowth.com). Canopy Growth is the world’s premier cannabis company that operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. Under this licensing agreement, Canopy Growth will have the right to manufacture and distribute the Company's "Pot-O-Coffee" and "Pot-O-Tea" branded marijuana infused single serve K-Cup products in Canada and certain other markets internationally as federal regulations allow. Licensed products include caffeinated and de-caffinated product lines as well as Isodiol's single serve "Pot-O-Coco". In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the "Pot-O" brand products in any territory outside of the US, Mexico and Puerto Rico. This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world. We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence," stated Isodiol's CEO Marcos Agramont. The availability of the various licensed products in Canada and elsewhere will differ depending on applicable laws and regulation. While Canadian law does not yet permit the manufacture and sale of marijuana infused products, the Company anticipates that such products will be permitted in the near future. Furthermore, currently proposed regulations which would permit the sale of infused products, would not allow such products to contain both marijuana and caffeine. As such, the specific product offerings in Canada and elsewhere may be limited. The Company will provide additional updates as regulations are adopted and as product roll-out plans are developed.

Isodiol International Inc. announces corporate update Update: https://isodiol.com/isodiol-international-inc-announces-co/... #Isodiol #Sales #JuneSales #QuartelySales #LatinAmerica #Isoderm Isodiol today released its unaudited consolidated sales figures for the month of June 2017. The company recorded sales of $1,843,173 CAD for the thirty-day period ended June 30, 2017. Total quarterly sales were $4,919,693 CAD for the period April 1st to June 30th, 2017. Isodiol International CEO Marcos Agramont stated, We continue to expand our domestic footprint and expand our distribution channels for our product lines. Month over month, we have grown by 10% and will continue to expand our sales and marketing team. With the progress we have made in Latin America and with our domestic growth, we are very excited entering the second half of 2017.

Isodiol International Inc. receives regulatory (ANVISA) approval for Isoderm for the treatment of Epilepsy and Parkinson's Release: https://isodiol.com/isodiol-international-inc-receives-reg/... #Epilepsy #Parkinsons #Brazil #Treatment #Isoderm #Cannabidiol #CBD #Isodiol #ANVISA #Pharmaceutical Isodiol is pleased to announce it has received approval from the Brazilian Health Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade Cannabidiol (CBD) product, Isoderm. This product will be placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and neurologists. Isodiol International CEO Marcos Agramont stated, We had initially anticipated this process to lead us into the third quarter, however receiving the first approval in a few months shows the quality and market demand for our Isoderm product. We anticipate additional product and medical indication approvals to continue over the coming weeks and months. We will strengthen our distribution relationships in the region and continue working towards receiving product approvals in other jurisdictions. We will continue to be proactive and mitigate the regulatory risk in North America by increasing our footprint in countries that have approved medical CBD. By increasing our global presence, we feel we will be in a position to influence the regulatory and legal framework of this movement into a sustainable industry domestically in Canada and the US. Additional information will be provided in the coming weeks around the progress of distribution partnerships.

Isodiol International Inc. establishes operations in Mexico and will commence shipment of cannabinol products News Release: https://isodiol.com/isodiol-international-inc-establishes-/ ... #Mexico #MexicanMarket #Legalization #Cannabis #CentralAmericanMarket #Isodiol #PharmaceuticalGradeCBD #CBDMovement Isodiol International Inc. a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has established operations in Mexico and will commence shipment of its Cannabinol products throughout Mexico within the coming weeks. With the Monday June 19th, 2017 announcement by Mexican President Enrique Pena Nieto, Mexico has now officially legalized Medical Marijuana. The bill legalizes the buying, selling, importing and exporting of cannabis products with less than 1% THC. Cannabis related products are now available for medical use and gives people in Mexico access to products containing THC for the first time. CEO of Isodiol International Inc. Marcos Agramont stated, Anticipating the medical cannabis legalization in Mexico, we have spent the last few months investing in infrastructure to expand our distribution into that market. Through our online sales platform, we will immediately be able to commence distribution and build a footprint within Mexico. We will also continue to work through the approval process with Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS) for our manufacturing permit which will allow us to produce in Mexico. This is a very important step for us, as we continue to build out a fully vertically integrated operation, which is being replicated domestically and in every market we enter. The company will provide additional information in the coming weeks.